Clinical Trial Update: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas [Phase 1]

View source ↗

Summary

Phase 1 neoadjuvant trial investigating camrelizumab with palbociclib for resectable esophageal squamous cell carcinoma; the study is currently active and not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Palbociclib (palbociclib)

Snippet

Sponsor: West China Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING